ClinicalTrials.gg
RecruitingNCT07556224Updated Apr 29, 2026

Evaluating the Efficacy and Short-Term Prognosis of Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis(AS): A Protocol for a Cohort Study

An observational study in Ankylosing Spondylitis (AS), sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by China-Japan Friendship Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
790
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Spondylitis, Ankylosing with a site in China — 20 open to participants now, 23 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Planned enrollment
5th of 15
790 · median 400
Started
2026
with 7 others
Observational
15 of 77
7 open now
Primary completion
2027-12
later than 15 of 22 live
Registered
70th of 77
by date
Lead sponsor
4 of 77
China-Japan Friendship Hospital

Among the 77 studies in Spondylitis, Ankylosing with a site in China, this one is the 5th largest by planned enrollment of the 15 observational ones that give a count, is one of 8 that started in 2026, is one of 15 observational ones, reaches primary completion later than 15 of the 22 other live ones, and was the 70th registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

20 of the 77 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, prospective cohort study designed to systematically evaluate the clinical efficacy of integrated Traditional Chinese and Western Medicine on short-term functional improvement in patients with ankylosing spondylitis, with the Bath Ankylosing Spondylitis Functional Index (BASFI) at 6 months of treatment as the primary outcome measure.

03

Conditions studied

  • Ankylosing Spondylitis (AS)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with Ankylosing spondylitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • fulfill the 1984 modified New York criteria for ankylosing spondylitis or the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis
  • age between 18 and 75 years
  • sign .

Exclusion criteria

Exclusion Criteria:

  • diagnosis of other diseases besides the disease under investigation (e.g., rheumatoid arthritis, Sjögren's syndrome, erythema nodosum, myositis, etc.)
  • pregnancy or lactation
  • comorbid severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, or
  • spondyloarthritis related to enteropathic arthritis, psoriatic arthritis, or reactive arthritis
  • unable to provide data due to mental, language, or similar factors.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
790 participants (estimated)
Patient registry
No

Groups and cohorts

  • exposed group

    Participants who receive integrated Traditional Chinese and Western Medicine therapy during the follow-up period.

  • non-exposed group

    Participants who receive only Western medicine therapy during the follow-up period.

06

What researchers measure

Primary outcomes

  1. The Bath Ankylosing Spondylitis Functional Index (BASFI)

    The Bath Ankylosing Spondylitis Functional Index (BASFI) is a 10-item instrument used to measure functional limitation in patients with ankylosing spondylitis. Each item is scored on a 0 to 10 visual analog scale, where 0 indicates easy and 10 indicates impossible. The total score is calculated as the mean of the 10 item scores and ranges from 0 to 10. Higher scores indicate worse functional status.

    Time frame: At baseline, 6 months.

Secondary outcomes

  1. The Bath Ankylosing Spondylitis Functional Index (BASFI)

    The Bath Ankylosing Spondylitis Functional Index (BASFI) is a 10-item instrument used to measure functional limitation in patients with ankylosing spondylitis. Each item is scored on a 0 to 10 visual analog scale, where 0 indicates easy and 10 indicates impossible. The total score is calculated as the mean of the 10 item scores and ranges from 0 to 10. Higher scores indicate worse functional status.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  2. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a 6-item instrument used to measure disease activity in participants with ankylosing spondylitis. It evaluates fatigue, spinal pain, peripheral joint pain and swelling, localized tenderness, and morning stiffness (severity and duration) over the past week. Each item is scored on a 0 to 10 scale, with higher scores indicating greater disease activity. The total BASDAI score is calculated as 0.2 × (Item 1 + Item 2 + Item 3 + Item 4 + (Item 5 + Item 6)/2) and ranges from 0 to 10. Higher scores indicate worse disease activity. A BASDAI score of 4 or higher is commonly considered to indicate high disease activity.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  3. Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP)

    The Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is a composite index used to measure disease activity in participants with ankylosing spondylitis. It combines patient-reported items and C-reactive protein (CRP) levels into a single score. The minimum score is 0, with lower scores indicating lower disease activity and higher scores indicating worse disease activity. There is no fixed maximum value because the upper end of the scale depends on the CRP level. ASDAS-CRP disease activity states are defined as inactive disease (\<1.3), moderate disease activity (1.3 to \<2.1), high disease activity (2.1 to ≤3.5), and very high disease activity (\>3.5). Clinically important improvement is defined as a decrease of at least 1.1 units, and major improvement is defined as a decrease of at least 2.0 units.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  4. The Bath Ankylosing Spondylitis Metrology Index (BASMI)

    The Bath Ankylosing Spondylitis Metrology Index (BASMI) is an instrument used to measure axial skeletal mobility in participants with ankylosing spondylitis. The total score ranges from 0 to 10. Lower scores indicate better spinal and hip mobility, while higher scores indicate greater limitation of movement and worse axial mobility.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  5. The Ankylosing Spondylitis Quality of Life Scale(ASQoL)

    The Ankylosing Spondylitis Quality of Life Scale (ASQoL) is a patient-reported instrument used to measure the impact of ankylosing spondylitis on health-related quality of life. The total score ranges from 0 to 18. Lower scores indicate better quality of life, while higher scores indicate worse quality of life.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  6. Pain Score on the Visual Analogue Scale (VAS)

    Pain due to ankylosing spondylitis measured on a 0 to 10 Visual Analogue Scale (VAS) over the past week, where 0 indicates no pain and 10 indicates the most severe pain. Higher scores indicate worse pain.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  7. Serum C-reactive protein (CRP) Level

    Serum C-reactive protein (CRP) level measured in blood as a laboratory marker of systemic inflammation in participants with ankylosing spondylitis. Higher CRP levels indicate greater systemic inflammation.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  8. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants who experience adverse events (AEs) or serious adverse events (SAEs), including gastrointestinal reactions, abnormal liver function, abnormal kidney function, and cardiovascular events, as identified from participant-reported symptoms, routine blood and urine tests, fecal occult blood tests, liver and kidney function tests, and electrocardiograms.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  9. Adherence to Prescribed Traditional Chinese Medicine and Western Medicine

    Adherence to prescribed traditional Chinese medicine and Western medicine during the 2-year follow-up period, based on participant-reported and recorded medication use.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  10. Time to Discontinuation of Western Medication

    Time from the first dose of Western medication to the permanent discontinuation of any Western medication used for ankylosing spondylitis, including non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs).

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

  11. Use of Non-steroidal Anti-inflammatory Drugs (NSAIDs)

    Use of non-steroidal anti-inflammatory drugs (NSAIDs) during the study period and changes over time, including NSAID type, dose, frequency, and duration, based on participant-reported and recorded medication use.

    Time frame: At baseline, 6 months, 12 months, 18 months, and 24 months post-enrollment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 47 non-industry observational studies under Spondylitis, Ankylosing, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 201. This study's planned 23 months is below that.

Counting every sponsor, half of 80 studies reached it within 47 months; a quarter within 27 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 29, 2026
StartActual
Jan 19, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07556224
Collaborators
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Guangxi Ruikang Hospital, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Beijing Electric Power Hospital, Hunan University of Traditional Chinese Medicine, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Xi'an Fifth Hospital, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital
Responsible party
Qingwen Tao (Chief physician, China-Japan Friendship Hospital) — Principal investigator
First posted
Apr 29, 2026
Start date
Jan 19, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Jiaqi Liu
Contact
benxiliujiaqi@163.com
+86 19804148523

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion